Q-Line Biotech IPO
Q-Line Biotech IPO Listing Day Performance
Q-Line Biotech listed on NSE SME on 29 May 2026 at ₹452.00, a 31.78% premium over the issue price of ₹343. A retail investor allotted the minimum application of 800 shares (2 lots) gained ₹87,200 at the listing price.
GMP vs actual listing
| Last GMP before listing | ₹125 (+36.4%) |
| GMP-implied listing | ₹468 |
| Actual listing | ₹452.00 |
| Difference | −₹16 (−3.4%) |
Demand going into listing
| Subscribed overall | 102.48× |
| QIB | 123.94× |
| NII | 146.33× |
| Retail | 71.42× |
Market Sentiment
IPO Details
Day-wise Subscription (times subscribed)
| Category | Day 1 | Day 2 | Day 3 | Day 5 |
|---|---|---|---|---|
| QIB | 4.15x | 5.19x | 5.19x | 123.94x |
| NII | 5.24x | 15.96x | 15.96x | 146.33x |
| bNII > ₹10L | 5.84x | 18.49x | 18.49x | 178.82x |
| sNII 2-10L | 4.03x | 10.90x | 10.90x | 81.35x |
| Retail | 3.61x | 9.92x | 9.92x | 71.42x |
| Total | 3.82x | 9.17x | 9.17x | 102.48x |
Market Lot Size
IPO Reservation
Financial Analysis
Financial Data
Financial Performance
| Metric | 2023 | 2024 | 2025 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 184.81 | 206.45 | 322.58 | 236.50 |
| Expense | 154.97 | 175.85 | 261.43 | 186.96 |
| Profit (PAT) | 32.10 | 34.44 | 28.13 | 38.69 |
| Total Assets | 251.58 | 339.25 | 455.49 | 561.34 |
Peer Comparison
| Company | EPS | P/E |
|---|---|---|
| Powerica Limited | 15.26 | 24.45 |
| Cummins India Limited | 72.15 | 64.13 |
| Kirloskar Oil Engines Limited | 33.71 | 43.24 |
| NTPC Green Energy Limited | 0.67 | 129.40 |
| Acme Solar Holdings Limited | 4.55 | 50.74 |
| Adani Green Energy Limited | 8.37 | 101.53 |
Promoters & Holding Pattern
Promoters: Saurabh Garg, Amita Garg, Ayush Garg, Ajay Kumar Mahanty and Abhay Agrawal
| Shareholding | No. of Shares | Holding % |
|---|---|---|
| Promoter Holding Pre Issue | 1,70,74,999 | 96.77% |
Strengths & Risks
- Heavily oversubscribed — 102.5x overall (so far).
- Strong institutional (QIB) demand — 123.9x.
- Revenue grew 56% in the latest reported year.
- Solid profit margin — 8.7%.
- Strong return on equity — 18%.
- Lists on the exchange's SME platform, where trading is usually thinner than on the main board — selling at your price can be harder.
From this issue's live data. Not investment advice — read the RHP.
Company Information
Q-Line Biotech at a glance
From the company's description: “Since its incorporation in 2013, Q-Line Biotech has been involved in the healthcare and diagnostic industry.”
Q-Line Biotech is raising ₹214 crore through an IPO on the NSE Emerge (SME). All of it is a fresh issue: there is no offer for sale, so every rupee raised goes to the company rather than to selling shareholders. Main stated uses of the fresh money: To meet Working Capital requirements (₹110 crore) and Repayment of certain borrowing availed by the Company, in part or full (₹90 crore).
Revenue went from ₹185 crore in 2023 to ₹323 crore in 2025, up 75% over 2 years. Profit after tax went from ₹32.1 crore to ₹28.13 crore, a net margin of 8.7% in the latest year.
Debt stands at 0.87 times equity.
Written from the issue's offer-document figures shown on this page. Not investment advice.
Company Contact Information
Q-Line Biotech Ltd., 298-281,, Transport Nagar,, Kanpur Road Adjacent Transport Nagar Metro Station, Lucknow, Uttar Pradesh, 226012
Objects of the Issue
| Purpose | Amount (Cr) |
|---|---|
| To meet Working Capital requirements | 110.00 |
| Repayment of certain borrowing availed by the Company, in part or full | 90.00 |
| General Corporate Purpose | - |
Resources & Documents
Anchor Investors
Q-Line Biotech IPO - Quick Take
Q-Line Biotech has set a price band of Rs 326–Rs 343 per share for an issue size of Rs 214 crore. The stock listed with a 31.78% gain versus its issue price on May 29, 2026.
The issue is promoted by Saurabh Garg, Amita Garg, Ayush Garg, Ajay Kumar Mahanty and Abhay Agrawal with Hem Securities Ltd., Share India Capital Services Pvt. Ltd. acting as lead manager. Net proceeds will primarily be used towards to meet Working Capital requirements (Rs 110 crore) and repayment of certain borrowing availed by the Company, in part or full (Rs 90 crore).
On fundamentals, the company is posting revenue growth of 56.3%, a profit margin of 8.7%, return on equity of 17.7% in its most recent reported period. Listed peers in this segment include Powerica Limited (P/E 24.45x) and Cummins India Limited (P/E 64.13x) — useful reference points when evaluating the issue's pricing relative to where the broader sector is trading.
On our data-signal score, the combined signals for this issue currently read strong — the composite picture tilts positive, though not without some caveats. This is a summary of public data, not a recommendation to apply or skip. Past performance does not predict future returns — review the price chart and peer comparison below before trading.
Q-Line Biotech IPO: Lead Manager & Registrar Track Record
How the firms running this issue and its registrar have fared on the other IPOs we track. Each firm's figures leave out Q-Line Biotech itself, so they describe what came before it.
- Q-Line Biotech listed at +31.8% on day one; the median of 193 listings was +1.5% (better than 81% of them).
- Subscribed 102x against a median of 3.98x across 192 issues (higher than 77%).
- Average listing-day move across all 194 SME listings we track: +11.6%.
| Firm | Other IPOs | Listed at / above issue | Avg move | Median |
|---|---|---|---|---|
| Hem Securities Ltd. Lead manager | 14 0 MB · 14 SME | 93% 13 of 14 | +29.2% | +16% |
| Share India Capital Services Pvt. Ltd. Lead manager | 5 1 MB · 4 SME | 80% 4 of 5 | +5.8% | +3% |
| Purva Sharegistry (India) Pvt.Limited. Registrar | 8 0 MB · 8 SME | 50% 4 of 8 | Check allotment → | |
Recent listings managed by Hem Securities Ltd. (5)
Best: Vans Electroengineerings +90% · Weakest: Kasturi Metal Composite −1.3%
| IPO | Listed | Listing-day move |
|---|---|---|
| HGS (India) | 06 Nov 2026 | +33.3% |
| Acme India Industries | 09 Oct 2026 | +12.8% |
| Vans Electroengineerings | 07 Oct 2026 | +90% |
| Century Business Media | 21 Sep 2026 | +0% |
| Raksan Transformers | 18 Sep 2026 | +0% |
Recent listings managed by Share India Capital Services Pvt. Ltd. (5)
Best: Oneindig Technologies +25% · Weakest: GRE Renew Enertech −8.6%
| IPO | Listed | Listing-day move |
|---|---|---|
| Pooja Logistics | 30 Sep 2026 | +2.6% |
| Oneindig Technologies | 06 Aug 2026 | +25% |
| Xtranet Technologies | 30 Jul 2026 | +7.1% |
| Happy Steels | 16 Jul 2026 | +3% |
| GRE Renew Enertech | 21 Jan 2026 | −8.6% |
A SEBI-registered merchant banker that runs the issue: due diligence, drafting the offer document, setting the price band with the company, and marketing the IPO to investors.
Finalises the basis of allotment, credits shares to demat accounts, releases blocked funds for unsuccessful bids and handles investor queries about the issue.
Listing-day move = exchange opening price vs issue price (band ceiling where the final price isn't recorded). Counts cover IPOs we track only. Past listings don't predict this one; this is not investment advice.
Frequently Asked Questions
Q-Line Biotech IPO GMP — What It Means
Its last GMP before listing was 36.4%. Of the 34 SME IPOs we have tracked with a final GMP of 25% or more, 34 listed above, 0 flat and 0 below the issue price; Q-Line Biotech listed 31.8% above its issue price.
See the full Q-Line Biotech GMP history and trend, or learn how grey market premium works and how reliable it is.
Related IPO
Same sector or same stage as Q-Line BiotechNo comments yet. Be the first to share your opinion!